CPP (Cancer Prevention Pharmaceuticals) Change In Receivables : $0.00 Mil (TTM As of Mar. 2016)

View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals Change In Receivables?

Cancer Prevention Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2016 was $0.00 Mil. It means Cancer Prevention Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2015 to Mar. 2016 .

Cancer Prevention Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2015 was $0.00 Mil. It means Cancer Prevention Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2014 to Dec. 2015 .

Cancer Prevention Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2016 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Cancer Prevention Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2016 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cancer Prevention Pharmaceuticals's liquidation value for the three months ended in Mar. 2016 was $-23.35 Mil.

Cancer Prevention Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals Change In Receivables Chart

Cancer Prevention Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Change In Receivables

Cancer Prevention Pharmaceuticals Quarterly Data
	Dec13	Dec14	Mar15	Sep15	Dec15	Mar16
Change In Receivables	Get a 7-Day Free Trial			-	-	-	-	-

Cancer Prevention Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Cancer Prevention Pharmaceuticals (AMEX:CPP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cancer Prevention Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2016 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	1.038	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Cancer Prevention Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Cancer Prevention Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2016 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8.692	-	32.039	+	0.75 * 0	+	0.5 * 0
=	-23.35

Cancer Prevention Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Prevention Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.canprevent.com

Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.